Biogen (BIIB +1.35%), one of the best performing big biotechs of 2013, reported solid third-quarter results today and hovered around an all-time high, but shares were up less than 1% when the market closed. In the following video, from The Motley Fool's health-care show Market Checkup, analysts Max Macaluso and David Williamson discuss the updated results from the launch of Biogen's newest multiple sclerosis drug, Tecfidera, and reasons why the company's hemophilia A drug Eloctate put a damper on today's results.
Another Big Win for Big Biotech Biogen?
By Max Macaluso, Dave Williamson, and Alison Southwick – Oct 28, 2013 at 6:55PM
NASDAQ: BIIB
Biogen
Market Cap
$22B
Today's Change
(1.35%) $2.00
Current Price
$149.86
Price as of October 30, 2025 at 3:58 PM ET
Biogen reported its third-quarter results, but was it all good news for the big biotech company?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo